IL15 and neoplasm: Other molecules that are being studied include NKTR-255, a novel polyethylene glycol-conjugate of rhIL-15 [177], and NIZ985, a recombinant heterodimer of IL-15/IL15Rα [178], both of which have shown promising anti-tumor efficacy in a preclinical and phase I clinical trial, respectively.